Effects of statins on triglyceride metabolism

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 32B-35B

  Ginsberg, Henry N ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b PH10 305   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CONFERENCE PAPER; DRUG EFFECT; DRUG SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 0032568084     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00035-6     Document Type: Conference Paper

References (19)

1. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;81(4A):66B-69B.
2. Dixon JL, Ginsberg HN. Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res 1993;34:167-179.
3. Bennett MK, Lopez JM, Sanchez HB, Osborne TF. Sterol regulation of fatty acid synthase promoter: coordinate feedback regulation of two major lipid pathways. J Biol Chem 1995;270:25578-25583.
4. Lopez JM, Bennett MK, Sanchez HB, Rosenfeld JM, Osborne TF. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci USA 1996;93:1049-1053.
5. Kawabe Y, Sato R, Matsumoto A, Honda M, Wada Y, Yazaki Y, Endo A, Takano T, Itakura H, Kodama T. Regulation of fatty acid synthase expression by cholesterol in human cultured cells. Biochem Biophys Res Com 1996;219:515-520.
6. Humble E, al-Shurbaji A, Lund E, Berglund L. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors. Biochim Biophys Acta 1994;1214:32-38.
7. Yanagita T, Yamamoto K, Ishida S, Sonda K, Morito F, Saku K, Sakai T. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Clin Ther 1994;16:200-208.
8. Khan B, Wilcox HG, Heimberg M. Cholesterol is required for secretion of very low density lipoprotein by rat liver. Biochem J 1989;258:807-816.
9. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen KC. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res 1992;33:1-7.
10. Krause BR, Newton RS. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1997;117:237-244.
11. Kasim SE, Elovson J, Khilnani S, Almario RU, Jen KL. Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat. Atherosclerosis 1993;104:147-152.
12. Maeda E, Yoshino G, Matsushita M, Nagata K, Morita M, Naka Y, Kazumi T. Effect of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on triglyceride kinetics in chronically streptozotocin-diabetic rats. Metabolism 1993; 42:52-57.
13. Shiomi M, Ito T. Pravastatin sodium, a competitive inhibitor of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases the cholesterol content of newly secreted very-low-density lipoprotein in Watanabe heritable hyperlipidemic rabbits. Metabolism 1994;43:559-564.
14. Huff MW, Telford DE. Regulation of low density lipoprotein apoprotein B metabolism by lovastatin and cholestyramine in miniature pigs: effects on LDL composition and synthesis of LDL subfractions. Metabolism 1989;38:256-264.
15. Ginsberg HN, Le N, Short MP, Ramakrishnan R, Desnick RJ. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implications for regulation of apolipoprotein B synthesis. J Clin Invest 1987;80:1692-1697.
16. Arad Y, Ramakrishnan R, Ginsberg HN. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J Lipid Res 1990;31:567-582.
17. Arad Y, Ramakrishnan R, Ginsberg H. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 1992;41:487-493.
18. Vega GL, Grundy SM. Effect of statins on metabolism of apo-β-containing lipoproteins in hypertriglyceridemic men. Am J Cardiol 1998;81(4A): 36B-42B.
19. Schonfeld G, Elias N. The role of HMG-CoA reductase inhibitors ("statins") in familial combined hyperlipidemia. Am J Cardiol 1998;81(4A):43B-46B.